Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Real-time Estimate Cboe BZX  -  05/16 12:11:55 pm EDT
130.94 USD   -1.46%
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
BU
05/11Asian ADRs Move Higher in Wednesday Trading
MT
05/10Asian ADRs Climb Higher in Tuesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Higher Ahead of Thursday's Close

01/20/2022 | 03:34pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
APTORUM GROUP LIMITED 0.00% 1.03 Delayed Quote.-31.33%
BEIGENE, LTD. 0.42% 132.76 Delayed Quote.-50.96%
NASDAQ COMP. -0.66% 11716.09 Real-time Quote.-24.54%
NOVOCURE LIMITED 5.32% 68.49 Delayed Quote.-13.11%
STAR EQUITY HOLDINGS, INC. 1.05% 0.7701 Delayed Quote.-70.11%
All news about BEIGENE, LTD.
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
BU
05/11Asian ADRs Move Higher in Wednesday Trading
MT
05/10Asian ADRs Climb Higher in Tuesday Trading
MT
05/09Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra..
MT
05/09INSIDER SELL : BeiGene
MT
05/09BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/05BeiGene Swings to Q1 Net Loss as Revenue Declines
MT
05/05Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $306.6M, vs. Street Est of $300.4M
MT
05/05BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
05/05BeiGene Reports First Quarter 2022 Financial Results
BU
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 399 M - -
Net income 2022 -1 403 M - -
Net cash 2022 3 140 M - -
P/E ratio 2022 -9,17x
Yield 2022 -
Capitalization 13 709 M 13 709 M -
EV / Sales 2022 7,55x
EV / Sales 2023 5,56x
Nbr of Employees 8 300
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 132,87 $
Average target price 312,13 $
Spread / Average Target 135%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-50.96%13 709
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601